🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

17 recruiting trials

for HER2+ Metastatic Breast Cancer (MBC)

Real-World Study on CDK4/6 Inhibitors Combined With Endocrine Therapy and Subsequent Treatment in HR+/HER2- MBC. NCT06033287n/a1 site📍 Changsha Hunan Cancer Hospital · Tests: Different treatment regimens following progression on CDK4/6 inhibitors. Treatment Monitoring of Patients Receiving CDK 4/6 Inhibitors for Hormone Receptor (HR) Positive, HER2 Negative Metastatic Breast Cancer (MBC) With or Without the Addition of DiviTum® Serum Thymidine Kinase 1 (TK1) Activity Testing NCT04968964NA1 site📍 St Louis Washington University School of Medicine · Tests: DiviTum® TKa assay, Study Care Plans Patient Navigation for HER2+ Metastatic Breast Cancer Patients Treated With Tucatinib NCT06983691NA1 site📍 Durham Duke University · Tests: Patient Navigation Program Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC NCT06263543Phase 23 sites📍 Miami📍 Atlanta📍 Fairway Reshma L. Mahtani, D.O. · Tests: Sacituzumab govitecan HER2 Targeted Molecular Imaging in mBC and Other Metastatic Solid Carcinomas Using 68Ga-ABS011 NCT06369831Phase 27 sites📍 Innsbruck📍 Brussels📍 Brussels Abscint NV/SA · Tests: 68Ga-NOTA-ABSCINT-HER2 PET/CT HER2-PET as a Precision Imaging Tool for Treatment With HER2-ADC in HER2-expressing mBC NCT06830382n/a1 site📍 Solna Renske Altena · Tests: Positron emission tomografy with [68Ga]Ga-ABY-025 ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer NCT07007559Phase 260 sites📍 Phoenix📍 Tucson📍 Duarte ALX Oncology Inc. · Tests: Evorpacept (ALX148), Trastuzumab, Paclitaxel, Capecitabine, Eribulin Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Breast Cancer w/Liver Dominant Disease NCT06875128Phase 28 sites📍 Santa Monica📍 Tampa📍 Cleveland Delcath Systems Inc. · Tests: Melphalan/HDS followed by Physician's choice of SOC (eribulin, vinorelbine, or capecitabine), Physician's cho… A Real-world Study Observing Treatment Patterns and Clinical Results for Patients in China With Hormone Receptor-positive, HER2-negative Metastatic Breast Cancer. NCT07743944n/a1 site📍 Nanjing AstraZeneca HER2 FPBMC in Patients With Metastatic Breast and Prostate Cancer (AM006) NCT07441889Phase 1, Phase 21 site📍 Charlottesville University of Virginia · Tests: HER2 FPBMC Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs. NCT06590857Phase 1, Phase 231 sites📍 Phoenix📍 Irvine📍 San Diego RayzeBio, Inc. · Tests: RYZ101, Standard of Care Endocrine Therapy Prospective Registry of ADC as First- and Second-line Treatment for Breast Cancer NCT06774027n/a3 sites📍 San Francisco📍 The Bronx📍 Durham University of California, San Francisco · Tests: Specimen collection, Non-Investigational Antibody-Drug Conjugates (ADC), Medical Record Review A Multicenter, Single-Arm, Phase II Exploratory Study of Eribulin in Combination With Anlotinib for HER2-Negative Recurrent/Metastatic Breast Cancer Previously Treated With Antibody-Drug Conjugates NCT07520760Phase 21 site📍 Guangzhou Sun Yat-sen University · Tests: Eribulin in Combination with Anlotinib Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread NCT06324357Phase 1, Phase 2104 sites📍 Cerritos📍 Los Angeles📍 Los Angeles Boehringer Ingelheim · Tests: Zongertinib, Trastuzumab deruxtecan, Trastuzumab emtansine, Trastuzumab, Capecitabine Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors NCT06784193Phase 125 sites📍 Gilbert📍 Aurora📍 Sarasota Olema Pharmaceuticals, Inc. · Tests: OP-3136, Fulvestrant, Palazestrant Integrated Testing Strategy for Simultaneous Detection of ESR-1 and gBRCA Mutations Via Liquid Biopsy in HR+/HER2- Metastatic Breast Cancer (mBC) Patients, NCT06762483n/a1 site📍 Milan European Institute of Oncology Patritumab Deruxtecan (U3-1402) in Unresectable Locally Advanced or Metastatic Breast Cancer NCT04965766Phase 211 sites📍 Dijon📍 Limoges📍 Lyon Gustave Roussy, Cancer Campus, Grand Paris · Tests: U3-1402
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy